Bronchitis Treatment Market to Grow with a CAGR of 5.37% through 2028
The aging population and ongoing medical research and
innovation are expected to drive the Global Bronchitis Treatment Market growth
in the forecast period, 2024-2028.
According to TechSci Research report, “Bronchitis
Treatment Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Bronchitis Treatment Market
stood at USD 5.73 billion in 2022 and is anticipated to grow with a CAGR of 5.37%
in the forecast period, 2024-2028. This can be attributed to medical device
innovations. Medical devices such as inhalers, nebulizers, and oxygen therapy
equipment are crucial for bronchitis management. Advances in these devices,
including improved portability and ease of use, are enhancing patient
compliance and driving market growth.
Moreover, drug repurposing, the practice of finding
new uses for existing medications, is gaining traction in bronchitis treatment.
Researchers are exploring the potential of repurposed drugs to alleviate
bronchitis symptoms or modify the course of the disease. This approach can
accelerate treatment development and reduce costs.
The emergence of the COVID-19 pandemic has resulted in
a decline in patient visits, leading to a reduced number of individuals seeking
treatment for bronchitis, thus exerting an impact on market growth. For
example, as outlined in a September 2020 published article titled
"Reduction in Ambulatory Visits for Acute, Uncomplicated Bronchitis: An
Unintended Yet Positive Outcome of the Coronavirus Disease 2019 (COVID-19)
Pandemic," the COVID-19 pandemic, though presenting challenges in various
facets of antimicrobial stewardship, has ultimately led to an overall decrease
in the number of adults seeking ambulatory care for bronchitis within the
healthcare system, resulting in a substantial reduction in antibiotic
prescriptions for this condition. Consequently, the initial phase of the
pandemic had an adverse effect on the market.
Furthermore, the market's growth is being driven by
several key factors, including the increasing elderly population with a higher
incidence of bronchitis, a rising prevalence of chronic obstructive pulmonary
disease (COPD), a growing number of smokers, and elevated levels of chemical
pollutants.
The escalating prevalence of COPD stands out as a
significant catalyst for market expansion. For instance, according to data from
NHS Digital in 2020-2021, approximately 1.17 million individuals in England
were diagnosed with COPD, representing around 1.9% of the population. Moreover,
as per a June 2021 update from the World Health Organization (WHO), chronic
obstructive pulmonary disease (COPD) ranks as the third leading cause of global
mortality, accounting for 3.23 million deaths in 2019. Consequently, the
increasing burden of COPD is driving a heightened demand for bronchitis
treatment, given that chronic bronchitis is a common precursor to COPD, thereby
making a substantial contribution to market growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Bronchitis Treatment Market”
The Global Bronchitis Treatment Market is segmented into
class of drugs, type, end user, regional distribution, and company.
Based on its class of drugs, it is anticipated that
the Bronchodilators Segment will exhibit substantial growth during the
projected period. Within the category of medicinal drugs, bronchodilators are
expected to capture a significant market share. These medications serve the
purpose of expanding airway passages and widening the windpipe, thereby
enhancing the respiratory function of individuals grappling with lung
infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD).
Bronchodilators stand as the primary pharmaceutical option for addressing
bronchitis by alleviating airway obstruction, a crucial factor in mitigating
breathing difficulties associated with chronic bronchitis.
Moreover, several key factors, including the
escalating incidence of respiratory ailments, the growing prevalence of
smoking, and the increasing number of product approvals, are propelling the
expansion of this market segment. Consequently, with the rising prevalence of
respiratory conditions, the demand for bronchodilators is poised to surge. For
example, according to a February 2022 report published by the National Center
for Bio, titled "Acute Bronchitis," it is estimated that more than 10
million office visits are recorded annually due to an acute bronchitis episode,
affecting approximately 5% of the general population each year. Hence, the
mounting burden of bronchitis is fueling the demand for bronchitis treatment,
thereby bolstering market growth.
Based on type, Acute Bronchitis is poised to secure a
substantial market share in the Global Bronchitis Treatment Market during the
forecast period for several compelling reasons. Firstly, the increasing
incidence of acute bronchitis cases worldwide is driving the demand for
effective treatment options. Secondly, the rising awareness among healthcare
professionals and patients about the importance of early diagnosis and prompt
treatment is contributing to the growth of the acute bronchitis segment.
Additionally, pharmaceutical companies are actively developing innovative
medications and therapies tailored specifically for acute bronchitis, further
expanding the market's offerings. Lastly, the burden of acute bronchitis on
healthcare systems and the economy is compelling governments and healthcare
organizations to prioritize its treatment, fostering market growth. As a
result, the acute bronchitis segment is expected to be a prominent player in
the Global Bronchitis Treatment Market in the coming years.
Major companies operating in Global Bronchitis
Treatment Market are:
- AstraZeneca PLC
- Novartis AG
- GSK PLC
- Dr. Reddy's Laboratories Ltd
- Sanofi SA
- Boehringer Ingelheim International
GmbH
- Pfizer Inc
- Melinta Therapeutics Inc
- Lupin Ltd
- Cadila Pharmaceuticals Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The global bronchitis treatment market is on the cusp
of significant transformation, driven by emerging trends that prioritize
personalized medicine, telehealth, targeted therapies, digital health
platforms, and patient-centric care. These trends hold the promise of
delivering more effective, efficient, and patient-friendly bronchitis
treatments in the future. Moreover, as research continues to uncover innovative
solutions and environmental initiatives gain momentum, the bronchitis treatment
landscape is set to evolve, providing new hope for patients and healthcare
providers alike,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Bronchitis Treatment Market By
Class of Drugs (Antibiotics, Anti-inflammatory
Drugs, Bronchodilator, Others), By Type (Acute Bronchitis, Chronic Bronchitis),
By End User (Hospital Pharmacies, Retail Pharmacies, Others), By Region, By Competition Forecast &
Opportunities, 2018-2028F”, has evaluated the future growth potential of Global
Bronchitis Treatment Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Bronchitis
Treatment Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com